drugset / Trial / NCT00057226

An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder

NCT00057226 ↗

Phase 2 Completed 365 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)

Timeline

Start
2003-03
Primary completion
2004-04
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Radafaxine Small molecule 40 mg Oral
Subject Radafaxine Small molecule 60 mg Oral